[ Price : $8.95]
FDA approves Johnson & Johnsons Tremfya (guselkumab) for treating adults with moderately to severely active ulcerative colitis.[ Price : $8.95]
Gilead Sciences says data from a second pivotal Phase 3 clinical trial investigating its twice-yearly injectable lenacapavir show ...[ Price : $8.95]
GSK moves its mRNA seasonal influenza vaccine program into Phase 3 after reporting favorable Phase 2 data.[ Price : $8.95]
Federal Register notice: FDA announces an 11/7 advisory committee meeting to review an IceCure Medical de novo request for its Pro...[ Price : $8.95]
FDA says it has added a Warning to labeling for Astellas Veozah about the risk of rare but serious liver injury.[ Price : $8.95]
A new National Academies book on collaboration in rare disease drug development lists steps it recommends that FDA take.[ Price : $8.95]
FDA publishes a guidance on submitting ANDA amendments under GDUFA 3.[ Price : $8.95]
Federal Register notice: FDA determines the regulatory review period for Cyclomedica Australias Technegas (technetium Tc 99m-label...